1. Show article details.

    BRIEF-Eli Lilly And Company To Hold 2020 Annual Meeting Of Shareholders Virtually

    Reuters – 12:02 PM ET 04/07/2020

    Eli Lilly and Co (LLY): * ELI LILLY AND COMPANY TO HOLD 2020 ANNUAL MEETING OF SHAREHOLDERS VIRTUALLY Source text for Eikon: Further company coverage:

  2. Show article details.

    Eli Lilly and Company to Hold 2020 Annual Meeting of Shareholders Virtually

    PR Newswire – 12:00 PM ET 04/07/2020

    INDIANAPOLIS, April 7, 2020  Eli Lilly and Company (LLY) announced today that due to the public health impact of the coronavirus outbreak, and to support the health and well-being of its employees, shareholders, and other meeting participants, the Board of Directors of Eli Lilly and Company (LLY) will hold the company's Annual Meeting of Shareholders scheduled for Monday, May 4, 2020 at 11:00 a.m. EDT in a...

  3. Show article details.

    BRIEF-Eli Lilly Says Does Not Currently Anticipate Shortages Of Any Forms Of Insulin During Covid-19 Crisis

    Reuters – 9:38 AM ET 04/07/2020

    Eli Lilly (LLY): * ELI LILLY AND CO SAYS NEW $35 CO-PAY NOW AVAILABLE THROUGH LILLY INSULIN VALUE PROGRAM IN RESPONSE TO COVID-19 CRISIS IN U.S. * DOES NOT CURRENTLY ANTICIPATE SHORTAGES OF ANY FORMS OF INSULIN DURING THE COVID-19 CRISIS.

  4. Show article details.

    Eli Lilly offers new $35 co-pay insulin value program during coronavirus pandemic

    MarketWatch – 6:38 AM ET 04/07/2020

    Eli Lilly& Co. said Tuesday it is introducing a Lilly Insulin Value Pogram, allowing anyone with insurance and those without insurance to fill their monthly insulin prescription for $35. The program has been launched with immediate effect and covers most Lilly insulins, the company said in a statement. Patients with diabetes can apply for a card by email or through the U.S. postal service and a card will typically be avaialable in 24 hours. "Too many people in the U.S. have lost their...

  5. Show article details.

    Eli Lilly lowers insulin costs as coronavirus crisis deepens

    Reuters – 6:33 AM ET 04/07/2020

    Drugmaker Eli Lilly & Co said on Tuesday it has capped the out-of-pocket cost for insulin to $35 per month to help diabetes patients across the United States, many of whom are facing financial difficulties due to the coronavirus outbreak.

  6. Eli Lilly offers new $35 co-pay through insulin value program during coronavirus pandemic

    MarketWatch – 6:32 AM ET 04/07/2020
  7. Show article details.

    New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.

    PR Newswire – 6:30 AM ET 04/07/2020

    INDIANAPOLIS, April 7, 2020  In response to the crisis caused by COVID-19, Eli Lilly and Company (LLY) is introducing the Lilly Insulin Value Program, allowing anyone with commercial insurance and those without insurance at all to fill their monthly prescription of Lilly insulin for $35. The program is effective today and covers most Lilly insulins including all Humalog® formulations.

  8. Show article details.

    Recession Blue-Chips' Led the Way in Another Turbulent Week in Markets

    DJ Business News – 7:14 AM ET 04/03/2020

    With the start of a new quarter, the market entered another stretch of volatility. The Dow Jones Industrial Average fell more than 4% Wednesday and swung more than 700 points from its high to its low Thursday before finishing the session up more than 2%. Crude oil once again approached $20 a barrel, before jumping 25% in a single session Thursday.

  9. Show article details.

    Healthcare stocks show their defensive allure in ailing market

    Reuters – 10:28 AM ET 04/02/2020

    The coronavirus pandemic is throwing a spotlight on stocks in the U.S. healthcare sector, home to the companies that could develop treatments, vaccines and improved diagnostics needed to tackle the greatest public health crisis in a century. Healthcare has held up better than most S&P 500 sectors.

  10. Show article details.

    Healthcare stocks show their defensive allure in ailing market

    Reuters – 10:20 AM ET 04/02/2020

    The coronavirus pandemic is throwing a spotlight on stocks in the U.S. healthcare sector, home to the companies that could develop treatments, vaccines and improved diagnostics needed to tackle the greatest public health crisis in a century. Healthcare has held up better than most S&P 500 sectors.

  11. Show article details.

    BRIEF-Medical Professionals Across Merck, Pfizer Inc, Eli Lilly To Support Health Systems

    Reuters – 4:11 PM ET 04/01/2020

    Eli Lilly and Co (LLY): * MEDICAL PROFESSIONALS ACROSS MERCK & CO., INC., PFIZER INC. (PFE), AND ELI LILLY AND COMPANY ACTIVATE TO SUPPORT HEALTH SYSTEMS, FIRST RESPONDERS AND PATIENTS AMID COVID-19 PANDEMIC Source text for Eikon: Further company coverage:

  12. Show article details.

    Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic

    Business Wire – 4:00 PM ET 04/01/2020

    Three leading biopharmaceutical companies have announced programs enabling employees with medical and laboratory expertise to volunteer their services to local healthcare systems and those hardest hit by COVID-19.

  13. Show article details.

    Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic

    Business Wire – 4:00 PM ET 04/01/2020

    Three leading biopharmaceutical companies have announced programs enabling employees with medical and laboratory expertise to volunteer their services to local healthcare systems and those hardest hit by COVID-19.

  14. Show article details.

    BRIEF-Lilly Endowment Reports Open Market Sale Of 38,962 Shares Of Eli Lilly Common Stock On March 31

    Reuters – 1:51 PM ET 04/01/2020

    Eli Lilly and Co (LLY): * LILLY ENDOWMENT REPORTS OPEN MARKET SALE OF 38,962 SHARES OF ELI LILLY COMMON STOCK AT AVERAGE PRICE OF $140.07PER SHARE ON MARCH 31 - SEC FILING Source text : Further company coverage:

  15. Show article details.

    U.S. court rules for Teva in migraine patent dispute with Eli Lilly

    Reuters – 1:23 PM ET 03/31/2020

    Teva Pharmaceutical Industries Ltd (TEVA) on Tuesday won a ruling from a U.S. administrative court that helps preserve its rights to the migraine drug Ajovy. The Patent Trial and Appeal Board rejected a challenge to three Teva patents relating to Ajovy brought by Eli Lilly and Co (LLY) .

  16. Show article details.

    BRIEF-Lilly And Sitryx Announce Collaboration To Discover And Develop New Immunometabolic Medicines

    Reuters – 7:37 AM ET 03/31/2020

    Eli Lilly and Co (LLY): * LILLY AND SITRYX ANNOUNCE LICENSING AND RESEARCH COLLABORATION TO DISCOVER AND DEVELOP NEW IMMUNOMETABOLIC MEDICINES. * ELI LILLY (LLY) - COLLABORATION TO STUDY UP TO 4 NOVEL PRECLINICAL TARGETS IDENTIFIED BY SITRYX THAT COULD LEAD TO POTENTIAL NEW MEDICINES FOR AUTOIMMUNE DISEASES. * ELI LILLY (LLY) -UNDER TERMS, SITRYX WILL RECEIVE AN UPFRONT PAYMENT OF $50 MILLION.

  17. Show article details.

    Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines

    PR Newswire – 6:30 AM ET 03/31/2020

    INDIANAPOLIS and OXFORD, England, March 31, 2020  Eli Lilly and Company (LLY) today announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.

  18. Show article details.

    BRIEF-Lilly's Taltz Receives U.S. FDA Approval For The Treatment Of Pediatric Patients

    Reuters – 7:01 AM ET 03/30/2020

    Eli Lilly and Co (LLY): * LILLY'S TALTZ® RECEIVES U.S. FDA APPROVAL FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS. * Eli Lilly and Co (LLY) - TALTZ ALSO MET ALL MAJOR SECONDARY ENDPOINTS IN STUDY Source text for Eikon: Further company coverage:

  19. Show article details.

    Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

    PR Newswire – 6:45 AM ET 03/30/2020

    INDIANAPOLIS, March 30, 2020 Eli Lilly and Company (LLY) announced today the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for Taltz® injection, 80 mg/mL for the treatment of pediatric patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

  20. Show article details.

    Drugmaker Vertex to delay new clinical studies due to coronavirus

    Reuters – 8:14 AM ET 03/27/2020

    U.S. drugmaker Vertex Pharmaceuticals Inc (VRTX) said on Friday it would delay starting some clinical trials and temporarily pause enrolment in some studies, as it looks to free up hospitals to deal with the coronavirus outbreak.

Page:

Today's and Upcoming Events

  • Apr
    23

    LLY to announce Q1 earnings (Confirmed)

Past Events (last 90 days)

  • Feb
    13

    LLY ex-Dividend for $0.74 on 02/13/2020

    • Announce Date: 12/16/2019
    • Record Date: 02/14/2020
    • Pay Date: 03/10/2020
  • Jan
    30

    LLY announced Q4 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.